PHK
ABCL icon

Point72 Hong Kong’s AbCellera Biologics ABCL Stock Holding History

Point72 Hong Kong’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,838
Closed -$345K – 44
2022
Q3 		$345K Buy
+34,838
New +$382K 0.01% 891
2021
Q4 		– Sell
-52
Closed -$1K – 1829
2021
Q3 		$1K Hold
52
– – ﹤0.01% 1890
2021
Q2 		$1K Hold
52
– – ﹤0.01% 1845
2021
Q1 		$2K Sell
52
-5,009
-99% -$200K ﹤0.01% 1702
2020
Q4 		$204K Buy
+5,061
New +$231K 0.01% 932

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Hong Kong's ABCL Position: Q4 2022 in Review

Point72 Hong Kong sold out of AbCellera Biologics (ABCL) in Q4 2022, closing a stake of 34,838 shares — an estimated $345K sold.

Point72 Hong Kong first reported a position in ABCL in Q4 2020 and held it in 5 quarters. The position peaked at $345K in Q3 2022. 201 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

  • Point72 Hong Kong reported no remaining AbCellera Biologics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 34,838 AbCellera Biologics shares in Q4 2022, an estimated $345K.
  • Point72 Hong Kong first reported a position in AbCellera Biologics in Q4 2020 and held it in 5 quarters.
  • Point72 Hong Kong's AbCellera Biologics position peaked at $345K in Q3 2022.
  • 201 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.